HRAS and head and neck squamous cell carcinoma: Although HRAS activity has previously been reported to contribute to most hallmarks of cancer [40] and to drive clinical resistance to cetuximab [42,43], it is also likely that HRAS-independent mechanisms contribute, at least in part, to the antitumor activity of tipifarnib in HNSCC models.